BioPharm Insight Releases Quarterly Licensing Information on Global Drug Development

Infinata’s leading life sciences publication highlights activity from the nation’s top law firms, revealing 3Q13 licensing activity decreased by 18% in value compared to 2Q13.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
It fuels their ability to make strategic long-term decisions about the competitive drug development market, using critical information before it’s available anywhere else.

Norwood, MA (PRWEB) December 03, 2013

On November 18, BioPharm Insight released its 3Q13 Licensing League Tables Report, reflecting an 18% decrease in pharmaceutical licensing by value since 2Q13. BioPharm Insight, part of Infinata, Inc., is a leading provider of business intelligence solutions and belongs to the Financial Times Group.

“BioPharm Insight subscribers have a distinct advantage with our quarterly Licensing League Tables,” said Ruth McHenry, Infinata’s managing director. “It fuels their ability to make strategic long-term decisions about the competitive drug development market, using critical information before it’s available anywhere else.”

The third quarter saw 120 agreements in the life sciences industry, with an aggregate disclosed value of $6.3 billion, a decrease from 2Q13, in which 121 agreements worth $7.6 billion were announced. The agreement between Ablynx and AbbVie, involving the drug ALX-0061, was the largest deal in 3Q13, potentially valued at $840 million.

Law firms Goodwin Procter and Duane Morris top the Global Licensing League Tables of Legal Advisors for the quarter. Based on information only available to editors at BioPharm Insight, Goodwin Procter tops the value table, having advised on three pharmaceutical drug licensing agreements, valued at $1.2 billion. Duane Morris leads the volume table with five transactions worth USD $933 million.

Download the full report here.

About BioPharm Insight
BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131

Media Inquiries: Brenda Nashawaty, Brenda[at]nashawaty[dot]com, 617-688-3253


Contact